Mirum Pharmaceuticals, Inc. (MIRM) · Oct 13, 2026 · Other events

Mirum Pharmaceuticals clinical trial clears every EXPAND endpoint

Above the bar — Primary endpoint met; all five prespecified secondary endpoints statistically significant

Mirum Pharmaceuticals’ EXPAND clinical trial met its primary endpoint and all five secondary endpoints, strengthening the case for a broader LIVMARLI label.

Mirum is using its established LIVMARLI franchise to expand beyond approved Alagille syndrome and PFIC indications into additional ultra-rare cholestatic liver diseases, while its broader pipeline advances other late-stage liver programs. This is a clean clinical win, not merely a primary-endpoint pass. EXPAND met its primary pruritus endpoint and achieved statistical significance across all five prespecified secondary endpoints, including the three tested in biliary atresia patients with a native liver. 〔0〕

EXPAND result	Maralixibat	Placebo	Treatment effect	p-value
Change in ItchRO(Obs) severity score, all pediatric patients	-1.81	-0.83	-0.98	0.0004
Relative change in total serum bile acids, overall population	-70.1%	-3.5%	-69.0%	<0.0001
Change in ItchRO(Obs), biliary atresia/native liver subgroup	-2.16	-1.01	-1.15	0.0002
Pruritus-improvement days, biliary atresia/native liver subgroup	96.4%	52.2%	44.1%	0.0045

The efficacy signal is broad and clinically relevant to the expansion thesis. The drug reduced itch severity by nearly one point versus placebo in the primary pediatric analysis and produced a 69.0% placebo-adjusted reduction in serum bile acids. The biliary-atresia/native-liver subgroup was at least as strong, which matters because that is a specific high-unmet-need population Mirum is trying to reach. 〔1〕

The main limitation is tolerability, not efficacy. Overall serious and grade 3-or-higher adverse-event rates were broadly similar between groups, but diarrhea was materially more common with maralixibat—64.0% versus 11.1% for placebo—and one treated patient discontinued. 〔2〕〔3〕 This does not overturn the readout, but regulators and prescribers will still weigh the benefit against gastrointestinal burden in a small, 52-patient study.

The result advances a known catalyst into a regulatory opportunity. EXPAND enrollment and the expected fourth-quarter 2026 data timing were already public, so the timing was partly known; the new information is that the study cleared every stated efficacy measure rather than only confirming a narrow primary-endpoint success. Mirum has indicated that the next named step is a U.S. supplemental application in the first half of 2027.

Bottom line: EXPAND materially strengthens Mirum’s LIVMARLI expansion story: efficacy was consistent across itch, bile acids, and biliary atresia, with no new safety signal. The remaining work is regulatory execution and proving that the gastrointestinal side effects are manageable in broader use.

What to watch next

U.S. sNDA submission, first half of 2027

Original filing on SEC EDGAR

More Mirum Pharmaceuticals, Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—

8-K events this week

—

filings analyzed in total

live · updated 30s ago

Live events · whole market · · --:--:-- ET

AllSight read

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

AllSight

Follow any company — we email you the moment it files, free!
Your watchlist saved to your account, on every device — free!

Limited-time offer

by Signing in NOW, claim your FREE 14-day Pro trial!

Every filing, live — decoded the instant it lands, zero delay from the SEC
Analyst-level reads — what changed, how it impacts, why it matters
The full read on every company — valuation, quality score, insider activity, analyst targets

That email doesn’t look right — try again.

Mirum Pharmaceuticals clinical trial clears every EXPAND endpoint

What to watch next

More Mirum Pharmaceuticals, Inc. news

Breaking down Wall Street's information edge.